Clinical trials: Re-irradiation
Nasopharyngeal Carcinoma
CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy
This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not…
- Trial name
- NCT07399158
- Volunteers
- 223 people
- Sponsor
- Fujian Cancer Hospital
Head and Neck Neoplasms
DAHANCA 37. Re-irradiation With Proton Radiotherapy
Summary Design Phase II observational Treatment 60 Gy/50 fx / 10W-1 at 1.2 Gy/fx o i.e. EQD2 tumor=56 Gy, EQD2 late=50.4 Gy at α/β= 10 and 3, respectively Proton radiotherapy Concomitant cisplatin for eligible patients*…
- Trial name
- NCT03981068
- Testing
- Re-irradiation
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Danish Head and Neck Cancer Group
Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy
Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer
This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.
- Trial name
- NCT04275687
- Testing
- thoracic irradiation, Concurrent chemotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab…
- Trial name
- NCT02289209
- Testing
- Reirradiation, MK-3475
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dan Zandberg
Squamous Cell Carcinoma of the Head and Neck
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
This study involves another course of radiation (called re-irradiation) to the participant's tumor. The type of radiation is called stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02158234
- Testing
- Cisplatin, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Brain Neoplasm
Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy
This pilot clinical trial studies the side effects and best dose of radiation therapy in patients with brain tumors that have come back after previous treatment with radiation therapy.
- Trial name
- NCT02698254
- Testing
- Bevacizumab, Quality-of-Life Assessment, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
NOA-12: BIBF1120 and R-RT in Glioblastoma
Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation can be included into the trial.
- Trial name
- NCT01666600
- Testing
- BIBF 1120, radiotherapy
- Where
- 2 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Prof. Dr. Wolfgang Wick
Metastatic Spine Lesions
Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery
This is a phase I clinical trial investigating the use of single fraction re-irradiation following local progression of spine and cauda equina (L2 to sacrum) lesions that have previously received radiation therapy.
- Trial name
- NCT02278744
- Testing
- single-fraction radiation, MRI and/or CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Intrinsic Pontine Glioma
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
Prospective, non-blinded, randomised two cohorts study on the efficacy of two different radiotherapy schedule for DIPG by using the same concomitant and post-radiotherapy systemic treatment.
- Trial name
- DIPG (NCT03620032)
- Testing
- Nimotuzumab, Vinorelbine, Radiotherapy
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lung Cancer, Non-Small Cell Lung Cancer
PET CT Re-Planning NSCLC (4DCT-PET)
This study will see whether the addition of more frequent planning CTs during the course of radiation, and of Positron Emission Tomography (PET), a diagnostic test similar to CT, prior to and during a course of radiation may…
- Trial name
- NCT03403127
- Testing
- PET/CT Scans
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
NSCLC
Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.
Patients with lung cancer may develop a second primary tumor or recurrent disease after previous radiotherapy. Surgical salvage therapy is the mainstay of therapeutic options.
- Trial name
- NCT02029222
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht Radiation Oncology
Non-Hodgkin Lymphoma
'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL
This is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) patients…
- Trial name
- NCT04601831
- Testing
- Focal radiation therapy (RT)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent Gynecologic Cancer, Recurrent Uterine Cancer
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total…
- Conditions
- Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer
- Trial name
- Regynera-RT (NCT07667192)
- Testing
- Reirradiation, Total Ablative Strategy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Cancer
Breast Re-irradiation After Second Ipsilateral Lumpectomy
The purpose of this research study is to test the safety and possible harms of treating breast cancer with reirradiation, after breast surgery.
- Conditions
- Breast Cancer, Cancer, Cancer of the Breast, HER2-negative Breast Cancer
- Trial name
- BRASIL (NCT06867484)
- Testing
- Intensity modulated radiation therapy (IMRT)
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Youssef Zeidan
Prostate Cancer
Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin
This phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin
- Trial name
- REPAIR (NCT04536805)
- Testing
- Metformin, Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy), Stereotactic Body Radiation Therapy (SBRT) 36 Gy
- Where
- 12 sites in France
- Volunteers
- 44 people
- Sponsor
- Institut Cancerologie de l'Ouest
Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent…
- Conditions
- Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- RETICULA-NPC (NCT04921995)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma HNSCC
Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.
- Trial name
- NCT07545967
- Testing
- Chidamide, radiotherapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Head and Neck Cancer
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00891904
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
- Trial name
- NCT03743662
- Testing
- Re-irradiation (RT), Bevacizumab, Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center